START Midwest Report issue

Academic/Hospital Phase 1

Organization Overview

First Clinical Trial
2020
NCT04641871
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

START Midwest | START Midwest, USA

Active Ingredients

Drugs in Phase 1 Trials (4)

sym021 (2 trials)

sym022 (1 trial)

sym023 (1 trial)

sym024 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasm Metastasis (Phase 1)

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 4